RT Journal Article
SR Electronic
T1 Assessing the Tendency of 2019-nCoV (COVID-19) Outbreak in China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.09.20021444
DO 10.1101/2020.02.09.20021444
A1 Qinghe Liu
A1 Zhicheng Liu
A1 Deqiang Li
A1 Zefei Gao
A1 Junkai Zhu
A1 Junyan Yang
A1 Qiao Wang
YR 2020
UL http://medrxiv.org/content/early/2020/04/16/2020.02.09.20021444.abstract
AB Since December 8, 2019, the spread of COVID-19 is increasing every day. It is particularly important to predict the trend of the epidemic for the timely adjustment of the economy and industries. We performed the trends of 2019-nCoV (COVID-19) in China based on Flow-SEHIR model.The results show that the basic reproductive numbers R0 of COVID-19 is 3.56 (95% CI: 2.31 – 4.81). The number of daily confirmed new cases reaches the inflection point on Feb. 6 – 10 outside Hubei. For the maximum of infected cases number, the predicted peak value in China except Hubei was estimated to be 13806 (95% CI: 11926 - 15845). The peak arrival time is on March 3 - 9. The peak cumulative number of patients in Hubei was estimated to be 63800 (95% CI: 59300 - 76500). The temporal number of patients in most areas of China outside Hubei will peak from March 12 to March 15. The peak values of more than 73.5% provinces or regions in China will be controlled within 1000.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno funding supportAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data are publicly available from the network http://qianxi.baidu.com/ http://www.nhc.gov.cn http://ynswsjkw.yn.gov.cn/wjwWebsite/web/index http://wjw.beijing.gov.cn/ http://wjw.hubei.gov.cn/ NCPNovel Coronavirus PneumoniaCOVID-19Coronavirus Disease 2019SARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2CIConfidence IntervalSEIRSusceptible-Exposed-Infectious-Recovered